Welcome to the official InxMed website
研发管线

研发管线

>
新一代抗体偶联小分子药物(ADC)

新一代抗体偶联小分子药物(ADC)

ADC has emerged as an important modality to deliver drugs with improved precision, and will remain an important modality against cancer. InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing.  We firmly believe that we can develop ADCs  for tumor selective across with relatively broad spectrum but also relatively normal tissue sparing.  
Our next generation ADCs will be entering IND enabling study in Q3  2024 and will address the key unmet medical need.

 InxMed

我们致力于开发针对肿瘤耐药和转移的创新疗法

快速链接

联系我们

电话: 025-58251030
邮箱: office@inxmed.com
公司地址: 南京市江北新区探秘路73号树屋十六栋D-2栋3层

在线留言

关注我们:

CopyRight © 2022 应世生物 All Rights Reserved.

网站建设: 中企动力 苏州